Primary Recipient

UNIVERSITY OF TEXAS M D ANDERSON

Amount

$124,612.00

Award Date

9/30/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

CML (chronic myeloid leukemia) is unique in that the BCR/ABL oncogene drives disease onset and progression. Therapies inhibiting the BCR/ABL kinase, such as imatinib mesylate, have dramatically altered the treatment of chronic phase disease, but are less